Financial Performance - Net loss for Q2 2024 was $20.4 million, an increase from $13.4 million in Q2 2023, primarily due to higher research and development expenses[7]. - General and administrative expenses decreased to $3.4 million in Q2 2024 from $3.6 million in Q2 2023[8]. - Cash used in operating activities for the six months ended June 30, 2024, was $(29,187) thousand, compared to $(22,885) thousand for the same period in 2023, representing an increase in cash outflow of approximately 27.7%[16]. - Total liabilities rose to $15,638 thousand from $12,684 thousand, reflecting an increase of about 23.0%[14]. - The accumulated deficit increased to $(433,764) thousand from $(399,582) thousand, indicating a decline in retained earnings[15]. - Total stockholders' equity increased to $65,788 thousand from $60,141 thousand, reflecting an increase of approximately 9.0%[15]. Research and Development - Overall response rate (ORR) increases to 33% across all evaluable patients and 38% for left-sided CRC patients in the Phase 2 DeFianCe study evaluating DKN-01[2]. - Research and development expenses rose to $17.9 million in Q2 2024 from $11.1 million in Q2 2023, driven by increased clinical trial costs[7]. - Enrollment in Part B of the DeFianCe study expanded to 180 patients, with completion expected by the end of September 2024[4]. - Initial data from the randomized controlled Part C of the DisTinGuish study is anticipated in Q4 2024 or early 2025[5]. - The company expects to report initial data from both randomized controlled studies over the next 12 months[3]. Cash and Assets - Cash and cash equivalents totaled $78.5 million as of June 30, 2024[8]. - Cash and cash equivalents at the end of the period were $78,479 thousand, compared to $70,643 thousand at the end of the previous period, marking an increase of approximately 11.5%[16]. - The company reported a net increase in cash and cash equivalents of $23,558 thousand for the three months ended June 30, 2024, compared to a net decrease of $(10,623) thousand in the same period in 2023[16]. - Total current assets increased to $79,587 thousand from $71,597 thousand, representing an increase of approximately 11.1%[14]. - Total assets increased to $81,426 thousand from $72,825 thousand, representing an increase of approximately 11.0%[14]. - Cash provided by financing activities was $37,117 thousand for the three months ended June 30, 2024, compared to no cash provided in the same period in 2023[16]. Clinical Outcomes - Median progression-free survival (PFS) for left-sided tumor patients was 8.6 months, unchanged from previous data[4]. - Research and development incentive receivable decreased slightly to $754 thousand from $771 thousand[14].

CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other juris ...

Exhibit 99.1 Leap Therapeutics Reports First Quarter 2024 Financial Results Cambridge, MA – May 13, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: "We appreciate the strong support of Gilead and the new and existing institutional investors who participated in our recent $40 million financing that will enable the expansion and co ...

Drug Development - The company is developing investigational drugs DKN-01 and FL-301, which are currently undergoing clinical trials and have not yet been approved by the FDA[12] - The company anticipates potential market opportunities for DKN-01 and FL-301, with ongoing collaborations with BeiGene, NovaRock, and Adimab to enhance development efforts[8] - The company is focused on the timing and results of its preclinical studies and clinical trials, which are critical for the advancement of its product candidates[8] - The company acknowledges various risks and uncertainties that could impact its future performance, including competition and regulatory approval timelines[9] - The company is aware of potential delays in clinical trials and manufacturing due to global conflicts or supply chain issues[9] Financial Considerations - The company is assessing its capital requirements and may seek additional financing to support its product development plans[8] - The company has not provided specific revenue figures for the quarter, but it emphasizes the importance of market acceptance for its investigational products[8] - The company has not disclosed specific financial results in this report, but it emphasizes the need for careful monitoring of its financial condition and liquidity[9] - The company has not provided specific guidance for future earnings or revenue, highlighting the uncertainty in the current market environment[9] Intellectual Property - The company is committed to maintaining and protecting its intellectual property rights as part of its growth strategy[8]

Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Cambridge, MA – March 18, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: "As we reflect on the fourth quarter and the achievements of the past year, we are proud of the strides we've made in advancing DKN- 01 and integrating o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other juris ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) 27-4412575 (I.R.S. Employer ...